Immunotherapy of Fungal Infections

Area of Science:

• Medical Mycology
• Immunology
• Infectious Diseases

Background:

• Fungal infections (mycoses) pose significant health risks, particularly invasive forms, with high morbidity and mortality.
• Current antifungal chemotherapy has limitations, driving the need for alternative or adjunct therapies.
• Host immunity plays a critical role in the outcome of fungal diseases, suggesting immunotherapy is a viable strategy.

Purpose of the Study:

• To review current research efforts in developing antifungal immunotherapies.
• To highlight the challenges and opportunities in translating basic research to clinical application for fungal diseases.
• To summarize various immunotherapeutic approaches for mycotic infections.

Main Methods:

• Review of ongoing research in antifungal immunotherapy.
• Exploration of diverse therapeutic modalities including vaccines, cell transfers, cytokines, antimicrobial peptides (AMPs), and monoclonal antibodies (mAbs).
• Analysis of challenges in fungal antigen peculiarities, host-pathogen interactions, and clinical translation.

Main Results:

• Despite decades of research, a significant gap exists between basic science discoveries and clinical application of antifungal immunotherapies.
• Various promising avenues are being explored, including novel vaccine designs, adoptive cell therapies, and targeted antibody treatments.
• Understanding complex host-pathogen interactions is crucial for effective immunotherapy development.

Conclusions:

• Antifungal immunotherapy holds significant potential as an adjunct to chemotherapy for invasive fungal diseases.
• Overcoming challenges related to fungal antigens, host immunity, and clinical translation is essential for therapeutic success.
• Continued research into vaccines, cell-based therapies, and other immunomodulatory agents is vital for advancing treatment options for mycotic infections.